Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | IDH2 | P48735 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14066799 | 0.85 | PIK3CG (0.48) | HDAC3HDAC1HDAC2HDAC6KDR | |
| SCHEMBL4601021 | 0.82 | KDR (0.46) | KMT2ASYKKDR | |
| SCHEMBL4600760 | 0.81 | KDR (0.49) | MEN1KMT2AKDR | |
| SCHEMBL6332844 | 0.81 | KDR (0.68) | KIF11IDH2KDR | |
| SCHEMBL15689102 | 0.78 | MEN1 (0.51) | HDAC3HDAC1HDAC2HDAC6MEN1 | |
| SCHEMBL4601487 | 0.78 | RAB9A (0.62) | HDAC6MEN1ALDH1A1KMT2AAURKA | |
| SCHEMBL12590910 | 0.78 | IDH2 (0.46) | KIF11IDH2THRBSYKKDM4E | |
| SCHEMBL5634358 | 0.76 | MAPK13 (0.56) | HDAC3HDAC1HDAC2HDAC6MEN1 | |
| SCHEMBL4601132 | 0.76 | KDR (0.62) | MEN1ALDH1A1KMT2AKDM4EKDR | |
| SCHEMBL5635378 | 0.75 | MAPK13 (0.70) | MEN1ALDH1A1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101273023-A | 5-substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-09-24 | — | — | CN | claimed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | claimed |
| EP-1912959-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-23 | — | — | EP | claimed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | claimed |
| CN-101273023-A | 5-substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-09-24 | — | — | CN | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| EP-1912959-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | BMX, CDK1, CKS1B | KIF11 958/4885HDAC3 2021/4885HDAC1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.